Faculty of Life Science, Northwestern Polytechnical University, Xi'an 710072, PR China.
Bioorg Med Chem Lett. 2010 Jan 1;20(1):164-7. doi: 10.1016/j.bmcl.2009.11.009. Epub 2009 Nov 10.
The development of new antibacterial therapeutic agents capable of halting microbial resistance is a chief pursuit in clinical medicine. Laterocidin and its analogues were synthesized for the first time by solid-phase synthesis method via linking of the carboxyl group on side chain of Aspartate to Rink resin with the protection of side chain alpha-carboxyl group of Aspartate by Dmab as a temporary alpha-COOH protecting group for the on-resin cyclization. Different configuration of N- and C-terminal was benefit to peptide cyclization. Laterocidin analogue 3 (Asp(1)-->Asn(1), Phe(4)-->Tyr(4) and d-Tyr(6)-->d-Phe(6)) demonstrated potent and broad antimicrobial properties, especially exhibited activity against clinical Methicillin-resistant Staphylococcus aureus (L-MRSA) and the gram-negative extended-spectrum beta-lactamases-producing Escherichia coli (ESBLs E. coli) and L-E.coli. This finding has important significance to exploit new antibiotic medicine.
开发能够阻止微生物耐药性的新型抗菌治疗药物是临床医学的主要追求。通过固相合成方法,首次合成了侧链天冬氨酸的羧基与 Rink 树脂相连的 laterocidin 及其类似物,并通过 Dmab 将天冬氨酸侧链 α-羧基保护为临时α-COOH 保护基,以保护侧链α-羧基。N-和 C-末端的不同构型有利于肽环化。Laterocidin 类似物 3(Asp(1)-->Asn(1),Phe(4)-->Tyr(4)和 d-Tyr(6)-->d-Phe(6))表现出强大而广泛的抗菌特性,特别是对临床耐甲氧西林金黄色葡萄球菌(L-MRSA)和革兰氏阴性产超广谱β-内酰胺酶的大肠杆菌(ESBLs E. coli)和 L-E.coli 具有活性。这一发现对于开发新型抗生素药物具有重要意义。